GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (NAS:CNTA) » Definitions » Liabilities-to-Assets

Centessa Pharmaceuticals (Centessa Pharmaceuticals) Liabilities-to-Assets : 0.34 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Centessa Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was $113.01 Mil. Centessa Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was $328.17 Mil. Therefore, Centessa Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 was 0.34.


Centessa Pharmaceuticals Liabilities-to-Assets Historical Data

The historical data trend for Centessa Pharmaceuticals's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals Liabilities-to-Assets Chart

Centessa Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Liabilities-to-Assets
- 2.91 0.22 0.24 0.34

Centessa Pharmaceuticals Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.30 0.31 0.34 0.34

Competitive Comparison of Centessa Pharmaceuticals's Liabilities-to-Assets

For the Biotechnology subindustry, Centessa Pharmaceuticals's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Centessa Pharmaceuticals's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Centessa Pharmaceuticals's Liabilities-to-Assets falls into.



Centessa Pharmaceuticals Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Centessa Pharmaceuticals's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Liabilities-to-Assets (A: Dec. 2023 )=Total Liabilities/Total Assets
=124.002/360.246
=0.34

Centessa Pharmaceuticals's Liabilities-to-Assets Ratio for the quarter that ended in Mar. 2024 is calculated as

Liabilities-to-Assets (Q: Mar. 2024 )=Total Liabilities/Total Assets
=113.008/328.171
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Centessa Pharmaceuticals  (NAS:CNTA) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


Centessa Pharmaceuticals Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Centessa Pharmaceuticals (Centessa Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
Executives
Harris Rotman officer: SVP Regulatory Affairs C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Antoine Yver officer: Chief Medical Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Tia L Bush officer: Chief Quality Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Karen M. Anderson officer: Chief People Officer C/O MIMECAST LTD., 191 SPRING STREET, LEXINGTON MA 02421
David J Grainger officer: Chief Innovation Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Gregory M Weinhoff officer: Chief Financial Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Thomas Templeman officer: Chief Technology Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
David M Chao officer: Chief Administrative Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Iqbal J Hussain officer: General Counsel C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH
Mathias Hukkelhoven director C/O CENTESSA PHARMACEUTICALS PLC, 3RD FL., 1 ASHLEY RD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Saurabh Saha director, officer: Chief Executive Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Javad Shahidi officer: Chief Medical Officer C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Medicxi Ventures Management (jersey) Ltd 10 percent owner C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Rubertis Francesco De director C/O MEDICXI, COURS DE RIVE 10, GENEVA V8 CH-1204
Aaron Kantoff director C/O CENTESSA PHARMACEUTICALS PLC, D. HODGKIN BLDG, BABRAHAM RSRCH CAMPUS, CAMBRIDGE X0 CB22 3FH

Centessa Pharmaceuticals (Centessa Pharmaceuticals) Headlines

From GuruFocus